Covid Vaccination Cuts Risk of Major Heart Events by Nearly 24%, Million-Veteran Study Finds

A massive new study has revealed an unexpected secondary benefit to Covid-19 vaccination: a dramatic reduction in major cardiovascular events. Published in JAMA Internal Medicine, the research suggests that the shots deliver meaningful heart protection far beyond their primary role of preventing acute respiratory illness.[1][3]

The study, led by researchers at the Veterans Affairs St. Louis Health Care System and Washington University, tracked more than one million U.S. veterans who received flu vaccinations in 2024. Roughly a third of this cohort also opted for an updated Covid-19 vaccine.[1][3]

Over the following eight months, the data revealed a striking divergence. Veterans who received the Covid-19 vaccine demonstrated a nearly 24 percent lower risk of all-cause cardiac events compared to those who only received the flu shot.[1][2]

This composite endpoint of "cardiac events" was broad and severe, encompassing heart attacks, strokes, hospitalizations for heart failure, and cardiovascular deaths. The sheer scale of the reduction has prompted researchers to reevaluate the systemic toll of the virus.[2][3]

Dr. Ziyad Al-Aly, the study's lead investigator, proposed a compelling hypothesis for these findings: millions of cardiac events currently tallied as "unexplained" or "idiopathic" likely have an invisible driver in the form of unrecognized SARS-CoV-2 infections.[1][3]

Many individuals who experience a brief, mild illness may never test for Covid-19, only to end up in an emergency room weeks later with a heart attack or stroke. Because the initial infection was undocumented, the subsequent cardiac event is rarely linked to the virus in official medical records.[1][6]

To understand how a respiratory virus triggers a heart attack, researchers point to the vascular damage caused by the pathogen. Severe, and even mild, Covid-19 infections can catalyze the growth of arterial plaques and destabilize existing ones.[4][6]

Furthermore, the virus is known to trigger a cascade of systemic inflammation. This inflammatory response damages the endothelial lining of blood vessels, creating a pro-thrombotic—or clot-prone—environment throughout the body.[4][5]

By preventing the acute infection entirely, or significantly blunting its severity, the vaccine effectively acts as a cardioprotective agent. It shields the vascular system from the intense inflammatory storm that leads to plaque rupture and clotting.[3][4]

When researchers narrowed their focus specifically to major adverse cardiovascular events (MACE) that were explicitly tied to a documented Covid-19 diagnosis, the protective effect was even more pronounced. The vaccine demonstrated a 37.7 percent effectiveness in preventing these direct, virus-associated cardiac emergencies.[2][3]

The benefits were heavily stratified by age. In a subgroup analysis, the vaccine's effectiveness against COVID-associated MACE was most statistically significant in adults older than 75, where it reached an impressive 50.7 percent.[2][3]

These findings stand in stark contrast to the persistent public anxiety surrounding Covid-19 vaccines and heart health. For years, discourse has been heavily influenced by concerns over myocarditis, an inflammation of the heart muscle.[5][6]

Extensive safety surveillance has consistently shown that vaccine-induced myocarditis is exceedingly rare, primarily affecting adolescent and young adult males. Crucially, the updated 2024-2025 and 2025-2026 mRNA formulations show myocarditis rates at or below two cases per million doses.[5][6]

This rate is virtually indistinguishable from the background rate of myocarditis in the general population. More importantly, the risk of developing myocarditis from an actual Covid-19 infection is roughly 20 times higher than the risk from the vaccine itself.[1][5]

Despite these clear cardiovascular benefits, public uptake of the updated Covid-19 vaccines remains sluggish, lagging significantly behind annual influenza immunization rates even among highly vulnerable demographics.[1][6]

The regulatory landscape has also shifted. In August 2025, the FDA restricted the approved use of the 2025-2026 Covid-19 vaccine to adults 65 and older, alongside younger individuals with documented high-risk health conditions.[1][6]

This policy change means that millions of Americans who might otherwise benefit from the vaccine's cardioprotective effects are no longer eligible to receive it under the standard approved indications, complicating public health messaging.[1][6]

Ultimately, the JAMA study marks a pivotal shift in how the medical community views the Covid-19 vaccine. It is increasingly recognized not merely as a seasonal shield against a week of respiratory misery, but as a critical, long-term intervention for preserving vascular health.[3][6]